Page 39 - Read Online

Li et al. Hepatoma Res. 2025;11:25 https://dx.doi.org/10.20517/2394-5079.2025.63 Page 17 of 17

68. Chen X, Huang Y, Chen H, et al. Augmented EPR effect post IRFA to enhance the therapeutic efficacy of arsenic loaded ZIF-8
nanoparticles on residual HCC progression. J Nanobiotechnology. 2022;20:34. DOI PubMed PMC
69. Xiao Z, Li T, Zheng X, et al. Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic
cell maturation and antigen presentation. Bioact Mater. 2023;21:57-68. DOI PubMed PMC
70. Minami Y, Kudo M. Image guidance in ablation for hepatocellular carcinoma: contrast-enhanced ultrasound and fusion imaging. Front
Oncol. 2021;11:593636. DOI PubMed PMC
71. Cao SE, Zhang LQ, Kuang SC, et al. Multiphase convolutional dense network for the classification of focal liver lesions on dynamic
contrast-enhanced computed tomography. World J Gastroenterol. 2020;26:3660-72. DOI PubMed PMC
72. Grazioli L, Ambrosini R, Frittoli B, Grazioli M, Morone M. Primary benign liver lesions. Eur J Radiol. 2017;95:378-98. DOI
PubMed
73. Bottari A, Silipigni S, Carerj ML, et al. Dual-source dual-energy CT in the evaluation of hepatic fractional extracellular space in
cirrhosis. Radiol Med. 2020;125:7-14. DOI PubMed
74. Granata V, Grassi R, Fusco R, et al. Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma. Infect
Agent Cancer. 2021;16:53. DOI PubMed PMC
75. Mathew RP, Sam M, Raubenheimer M, Patel V, Low G. Hepatic hemangiomas: the various imaging avatars and its mimickers. Radiol
Med. 2020;125:801-15. DOI PubMed
76. Fusco R, Granata V, Petrillo A. Introduction to special issue of radiology and imaging of cancer. Cancers. 2020;12:2665. DOI
PubMed PMC